Bearish
🤖 95%
Galderma Shares Plunge After FDA Rejects Botox Rival Relfydess
FDA rejection of Relfydess directly impacts Galderma's revenue growth prospects and pipeline value, leading to a sharp sell-off in its shares.
Catalysts
- ▼ FDA rejection of Relfydess
Risk Factors
- ▲ Galderma may successfully address FDA concerns rapidly
- ▲ Acquisition bid by larger pharma could support shares
▼ Show FAQ (3) ▲ Hide FAQ
Why is Galderma's stock falling?
The stock is falling because the FDA rejected its Relfydess application, delaying a key growth driver in the lucrative U.S. aesthetics market and casting doubt on the product's commercial timeline.
Will Galderma try again for FDA approval?
Yes, Galderma is expected to evaluate the FDA's feedback and likely conduct additional studies to address the concerns before resubmitting the application.
How much revenue could Galderma lose from this delay?
While precise figures aren't available, the U.S. medical aesthetics market is worth over $6 billion, and Botox holds a leading share. Galderma's delay means it will miss out on near-term revenue opportunity in that segment.